Gensight Biologics SA (SIGHT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Gensight Biologics SA (SIGHT) has a cash flow conversion efficiency ratio of 0.260x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-6.49 Million ≈ $-7.59 Million USD) by net assets (€-24.94 Million ≈ $-29.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SIGHT equity to assets ratio to measure how much of total assets are equity-financed.
Gensight Biologics SA - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Gensight Biologics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Gensight Biologics SA (SIGHT) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Gensight Biologics SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gensight Biologics SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tandy Leather Factory Inc
NASDAQ:TLF
|
0.019x |
|
Woojin I&S Co Ltd
KO:010400
|
-0.025x |
|
Formetal Co. Ltd
KQ:119500
|
0.033x |
|
Castile Resources Ltd
AU:CST
|
-0.018x |
|
Puloon Technology Inc
KQ:094940
|
0.062x |
|
AIRA Factoring Public Company Limited
BK:AF
|
-0.265x |
|
Jindo.Co. Ltd
KO:088790
|
0.016x |
|
ADS Maritime Holding Plc
OL:ADS
|
-0.043x |
Annual Cash Flow Conversion Efficiency for Gensight Biologics SA (2013–2025)
The table below shows the annual cash flow conversion efficiency of Gensight Biologics SA from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Gensight Biologics SA worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €-24.94 Million ≈ $-29.16 Million |
€-9.38 Million ≈ $-10.96 Million |
0.376x | -21.76% |
| 2024-12-31 | €-26.92 Million ≈ $-31.47 Million |
€-12.94 Million ≈ $-15.12 Million |
0.481x | -40.18% |
| 2023-12-31 | €-30.70 Million ≈ $-35.89 Million |
€-24.66 Million ≈ $-28.83 Million |
0.803x | -63.64% |
| 2022-12-31 | €-15.28 Million ≈ $-17.86 Million |
€-33.75 Million ≈ $-39.46 Million |
2.209x | +306.10% |
| 2021-12-31 | €15.99 Million ≈ $18.69 Million |
€-17.14 Million ≈ $-20.04 Million |
-1.072x | +16.87% |
| 2020-12-31 | €11.67 Million ≈ $13.64 Million |
€-15.04 Million ≈ $-17.59 Million |
-1.289x | +46.12% |
| 2019-12-31 | €11.75 Million ≈ $13.73 Million |
€-28.11 Million ≈ $-32.87 Million |
-2.393x | -101.28% |
| 2018-12-31 | €23.87 Million ≈ $27.91 Million |
€-28.38 Million ≈ $-33.18 Million |
-1.189x | -248.17% |
| 2017-12-31 | €55.00 Million ≈ $64.30 Million |
€-18.78 Million ≈ $-21.96 Million |
-0.342x | +7.26% |
| 2016-12-31 | €53.34 Million ≈ $62.36 Million |
€-19.64 Million ≈ $-22.96 Million |
-0.368x | +10.71% |
| 2015-12-31 | €29.33 Million ≈ $34.29 Million |
€-12.09 Million ≈ $-14.14 Million |
-0.412x | +20.91% |
| 2014-12-31 | €10.58 Million ≈ $12.37 Million |
€-5.52 Million ≈ $-6.45 Million |
-0.521x | -353.65% |
| 2013-12-31 | €16.97 Million ≈ $19.83 Million |
€-1.95 Million ≈ $-2.28 Million |
-0.115x | -- |
About Gensight Biologics SA
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV… Read more